MedTrace Logo

A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

NCT07491172 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-05-22

No results posted yet for this study

Summary

This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refractory to available treatments.

Conditions

  • Cardiovascular
  • Metabolic Disease
  • Dyslipidemias
  • Lipid Disorder
  • Hypertriglyceridemia
  • Heterozygous Familial Hypercholesterolemia (HeFH)
  • Homozygous Familial Hypercholesterolemia (HoFH)
  • Severe Hypertriglyceridemia (sHTG)
  • Mixed Hyperlipemia
  • Hypercholesterolaemia

Interventions

DRUG

CTX310

CTX310 is a lipid nanoparticle (LNP) formulation of clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 9 (Cas9) components for in vivo editing of the target gene angiopoietin-like 3 (ANGPTL3).

Sponsors & Collaborators

  • CRISPR Therapeutics AG

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-21
Primary Completion
2027-06-30
Completion
2028-06-30
FDA Drug
Yes

Countries

  • United States
  • Australia
  • New Zealand
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07491172 on ClinicalTrials.gov